Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab

Journal of Cellular Physiology

Volumn 204, Issue 2, 2005, Pages 463-469

  Biroccio, Annamaria ^a   D'Angelo, Carmen ^a   Jansen, Burkhard ^b   Gleave, Martin E ^b   Zupi, Gabriella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CLUSTERIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN; LIPOCORTIN 5; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OGX 011; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CLUSTERIN; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GLYCOPROTEINS; HUMANS; MOLECULAR CHAPERONES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RECEPTOR, ERBB-2;

EID: 20344402686     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20295     Document Type: Article

References (55)

1. Bettuzzi S, Hiipakka RA, Gilna P, Liao ST. 1989. Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem J 257:293-296.
2. Bettuzzi S, Troiano L, Davalli P, Tropea F, Ingletti MC, Grassilli E, Monti D, Corti A, Franceschi C. 1991. In vivo accumulation of sulfated glycoprotein 2 mRNA in rat thymocytes upon dexamethasone-induced cell death. Biochem Biophys Res Commun 175:810-815.
3. Biroccio A, Benassi B, Amodei S, Gabellini C, Del Bufalo D, Zupi G. 2001. c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharmacol 60:174-182.
4. Biroccio A, Benassi B, Filomeni G, Amodei S, Marchini S, Chiorino G, Rotilio G, Zupi G, Ciriolo MR. 2002. Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells. J Biol Chem 277:43763-43770.
5. Buttyan R, Olsson CA, Pintar J, Chang C, Bandyk M, Ng PY, Sawczuk IS. 1989. Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol 9:3473-3481.
6. Chi KN, Eisenhauer E, Fazli L, Jones EC, Powers J, Ayers D, Goldenberg SL, Gleave ME. 2004. ASCO proceeding.
7. Criswell T, Klokov D, Beman M, Lavik JP, Boothman DA. 2003. Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol Ther 2:372-380.
8. Debure L, Vayssiere JL, Rincheval V, Loison F, Le Drean Y, Michel D. 2003. Intracellular clusterin causes juxtanuclear aggregate formation and mitochondrial alteration. J Cell Sci 116:3109-3121.
9. Del Bufalo D, Biroccio A, Soddu S, Laudonio N, D'Angelo C, Sacchi A, Zupi G. 1996. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J Clin Invest 98:1165-1173.
10. Grossmann M, O'Reilly LA, Gugasyan R, Strasser A, Adams JM, Gerondakis S. 2000. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J 19:6351-6360.
11. Han BH, DeMattos RB, Dugan LL, Kim-Han JS, Brendza RP, Fryer JD, Kierson M, Cirrito J, Quick K, Harmony JA, Aronow BJ, Holtzman DM. 2001. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med 7:338-343.
12. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. 2001. Coordinately up-regulated genes in ovarian cancer. Cancer Res 61:3869-3876.
13. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. 1999. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274:6875-6881.
14. Jenne DE, Tschopp J. 1992. Clusterin: The intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 17:154-159.
15. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. 2002. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50:179-188.
16. July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME. 2004. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 3:223-232.
17. Kakehi Y, Ozdemir E, Habuchi T, Yamabe H, Hashimura T, Katsura Y, Yoshida O. 1998. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res 89:214-220.
18. Kalka K, Ahmad N, Criswell T, Boothman D, Mukhtar H. 2000. Up-regulation of clusterin during phthalocyanine 4 photodynamic therapy-mediated apoptosis of tumor cells and ablation of mouse skin tumors. Cancer Res 60:5984-5987.
19. Koch-Brandt C, Morgans C. 1996. Clusterin: A role in cell survival in the face of apoptosis? Prog Mol Subcell Biol 16:130-149.
20. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE. 2001. NF-kappaB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem 276:45380-45386.
21. Kurland JF, Voehringer DW, Meyn RE. 2003. The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis. J Biol Chem 278:32465-32470.
22. Lakins J, Bennett SA, Chen JH, Arnold JM, Morrissey C, Wong P, O'Sullivan J, Tenniswood M. 1998. Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J Biol Chem 273:27887-27895.
23. Lee CH, Jin RJ, Kwak C, Jeong H, Park MS, Lee NK, Lee SE. 2002. Suppression of clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells. Urology 60:516-520.
24. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. 2003. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278:11590-11600.
25. Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A, Cognetti F, Zangemeister-Wittke U, Del Bufalo D, Zupi G. 2004. Trastuzumab downregulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells. Clin Cancer Res (in press).
26. Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto H, Gohji K, Arakawa S, Kamidono S, Saya H. 1998. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 16:933-943.
27. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. 1999a. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells. Br J Cancer 79:1651-1656.
28. Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S. 1999b. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. J Urol 162:2176-2181.
29. Miyake H, Nelson C, Rennie PS, Gleave ME. 2000a. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60:170-176.
30. Miyake H, Nelson C, Rennie PS, Gleave ME. 2000a. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 60:2547-2554.
31. Miyake H, Chi KN, Gleave ME. 2000c. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6:1655-1663.
32. Miyake H, Hara I, Kamidono S, Gleave ME. 2001. Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 7:4245-4252.
33. Miyake H, Eto H, Hara I, So A, Li D, Gleave ME. 2004. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. J Urol 171:2477-2481.
34. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. 2001. Epidermal growth factor receptor (HERD1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895.
35. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S. 2002. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65-72.
36. O'Sullivan J, Whyte L, Drake J, Tenniswood M. 2003. Alterations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis. Cell Death Differ 10:914-927.
37. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. 2001. Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble rat. Carcinogenesis 22:965-973.
38. Parczyk K, Pilarsky C, Rachel U, Koch-Brandt C. 1994. Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 120:186-188.
39. Poon S, Easterbrook-Smith SB, Rybchyn MS, Carver JA, Wilson MR. 2000. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 39:15953-15960.
40. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. 2004. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23:2298-2304.
41. Reddy KB, Jin G, Karode MC, Harmony JA, Howe PH. 1996. Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 35:6157-6163.
42. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. 2000. Overexpression of clusterin in human breast carcinoma. Am J Pathol 157:393-399.
43. Rosenberg ME, Silkensen J. 1995. Clusterin: Physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 27:633-645.
44. Sensibar JA, Griswold MD, Sylvester SR, Buttyan R, Bardin CW, Cheng CY, Dudek S, Lee C. 1991. Prostatic ductal system in rats: regional variation in localization of an androgen-repressed gene product, sulfated glycoprotein-2. Endocrinology 128:2091-2102.
45. Simeone AM, Broemeling LD, Rosenblum J, Tari AM. 2003. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. Oncogene 22:6739-6747.
46. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM, Sensibar JA. 1997. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3:1707-1711.
47. Trougakos IP, Gonos ES. 2002. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 34:1430-1448.
48. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. 2004. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64:1834-1842.
49. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
50. Wehrli P, Charnay Y, Vallet P, Zhu G, Harmony J, Aronow B, Tschopp J, Bouras C, Viard-Leveugle I, French LE, Giannakopoulos P. 2001. Inhibition of post-ischemic brain injury by clusterin overexpression. Nat Med 7:977-979.
51. Wellmann A, Thieblemont C, Pittaluga S, Sakai A, Jaffe ES, Siebert P, Raffeld M. 2000. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96:398-404.
52. Wong P, Ulyanova T, Organisciak DT, Bennett S, Lakins J, Arnold JM, Kutty RK, Tenniswood M, vanVeen T, Darrow RM, Chader G. 2001. Expression of multiple forms of clusterin during light-induced retinal degeneration. Curr Eye Res 23:157-165.
53. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ, Boothman DA. 2000. Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 97:5907-5912.
54. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. 2001. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3:360-367.
55. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME. 2002. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8:3276-3284.